Last reviewed · How we verify
PSD502
At a glance
| Generic name | PSD502 |
|---|---|
| Sponsor | Plethora Solutions Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Virtual Reality for Port-a-Cath Access (NA)
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (PHASE2)
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2, PHASE3)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (PHASE1, PHASE2)
- The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment (PHASE1, PHASE2)
- Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children. (NA)
- Topical Anesthesia During Catheter Insertion for Cervical Ripening (TOLERANCE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PSD502 CI brief — competitive landscape report
- PSD502 updates RSS · CI watch RSS
- Plethora Solutions Ltd portfolio CI